Discontinuation report MODERIBA

Last updated on 2018-08-30
Report ID 31316
Drug Identification Number 02436418
Brand name MODERIBA
Common or Proper name MODERIBA TABLETS 400MG
Company Name ABBVIE CORPORATION
Active Ingredient(s) RIBAVIRIN
Strength(s) 400MG
Dosage form(s) TABLET
Route of administration ORAL
Packaging size 56 tablets per bottle
ATC code J05AB
ATC description DIRECT ACTING ANTIVIRALS
Reason for discontinuation Business reasons
Anticipated discontinuation date 2018-10-31
Actual discontinuation date 2018-08-02
Remaining supply date 2018-10-31
Discontinuation status Discontinued
Discontinuation decision reversal No
Information on remaining supply Last lot available on market expires on Oct-31st, 2018. Per AbbVie’s return policy, for your entire remaining inventory, we ask that you return product only at expiry.
Company comments This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market.
Health Canada comments
Contact Address 8401 TRANS-CANADA HIGHWAY
SAINT-LAURENT, QUEBEC
CANADA H4S 1Z1
Company contact information Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270.